Biogena Group Invest: Subscription Deadline Looms as Restructuring Story Gathers Pace

Shares surge 3.07% to €4.70 as subscription period for parent Biogena Good Vibes AG closes July 22. IPO planned August with €475M valuation; funds target production expansion.

With the clock ticking down on a €25 million capital raise, shares in Biogena Group Invest have surged to a fresh 52-week high of €4.70, adding 3.07% in Tuesday’s session. The rally extends a blistering run that has seen the stock climb nearly 40% over the past month alone, pushing year-to-date gains to roughly 59%. At the heart of the move lies a tense waiting game: the subscription period for new shares in parent company Biogena Good Vibes AG closes on 22 July at midnight CEST—and the outcome will shape the next chapter for the entire group.

The capital increase, which opened on 10 June, offers investors in Austria and Germany up to 4.16 million new ordinary shares at an issue price of €4.803 each. If the expansion option is fully exercised, the total could reach 5.2 million shares, giving the holding company a gross proceeds target of around €20 million, or up to €25 million. The funds are earmarked primarily for expanding production at the group’s Austrian site in Koppl near Salzburg, as well as strengthening its international distribution network.

While the stock’s recent ascent reflects optimism around the restructuring, market makers are watching the subscription book closely. A full take-up would signal strong institutional appetite ahead of an even bigger milestone planned for August this year: the listing of Biogena Good Vibes AG on the Direct Market Plus segment of the Vienna Stock Exchange. Media reports suggest management is seeking a valuation of roughly €475 million at the time of the IPO, a figure that would represent a stark contrast to the current market capitalisation of Biogena Group Invest—just €17.72 million.

The relationship between the two entities remains a key source of speculation. Employees and management already hold about 9% of the shares, and the current capital increase is designed to broaden the free float and attract more institutional investors. As for the possibility of a merger between the existing listed vehicle, Biogena Group Invest, and the new holding company, the Vienna Stock Exchange has indicated that such a move would only be examined after the IPO, likely in August 2026. No binding decision on timing or exchange ratio has been made.

Operationally, the group is pinning its growth ambitions on Germany, which CEO Schmidbauer describes as “the biggest growth opportunity” for Biogena. In the 2024/25 financial year the company generated revenue of around €125 million, and management has set a target of €500 million by 2030. For the current year, internal forecasts point to roughly €150 million, with investments flowing into the online shop, new store concepts, and the Austrian production hub.

Despite the sharp price appreciation, technical indicators suggest the rally is not yet overheated. The relative strength index stands at 64.8, sitting comfortably in the upper neutral range. The shares trade about 30% above their 50-day moving average of €3.62 and roughly 50% above the 200-day line at €3.13. Yet the degree of volatility is striking: the annualised 30-day volatility clocks in at 82.4%, a figure that underscores how news flow around the restructuring can whip the stock around on even modest trading volumes.

Looking back, the stock bottomed at €2.38 in July 2025, meaning the current price represents a gain of more than 67% over twelve months. That trajectory, however, has been built almost entirely on expectation rather than proven post-restructuring liquidity. The coming days will reveal whether the subscription period fills as planned, and come August the IPO will test the market’s appetite for the group’s €475 million valuation thesis. Only then will investors know whether this high-flying rally has found solid ground.